Back to Authors

Ayutyanont, Napatkamon

https://orcid.org/0000-0002-7102-2528

Mayo Clinic

Banner Alzheimer’s Institute

Citations 7

Alzheimer's Prevention Initiative: A Plan to Accelerate the Evaluation of Presymptomatic Treatments
Reiman, Eric M. , Fleisher, Adam , Caselli, Richard J. , Chen, Kewei , Ayutyanont, Napatkamon , Quiroz, Yakeel T. , Tariot, Pierre N. , Langbaum, Jessica B. S. , Kosik, Kenneth S. , Lopera, Francisco Javier

Journal of Alzheimer's Disease | May 16, 2018 | Volume: 26 | Issue: s3 | Pages: 321-329

10.3233/jad-2011-0059 Get It

P4‐298: IMPROVING THE POWER TO TRACK FIBRILLAR AMYLOID PET MEASUREMENTS AND EVALUATE AMYLOID‐MODIFYING TREATMENTS USING A CEREBRAL WHITE MATTER REFERENCE REGION‐OF‐INTEREST
Roontiva, Auttawut, Lee, Wendy , Ayutyanont, Napatkamon , Protas, Hillary , Landau, Susan , Luo, Ji , Bauer, Robert, Reschke, Cole, Bandy, Dan, Fleisher, Adam , Caselli, Richard J., Jagust, William J. , Weiner, Michael W. , Reiman, Eric M. , Chen, Kewei , Thiyyagura, Pradeep , Liu, Xiaofen , Koeppe, Robert A. , Caselli, Richard J.

Alzheimer's & Dementia | September 6, 2014 | Volume: 10 | Issue: 4S_Part_15 | Pages: No page available

10.1016/j.jalz.2014.07.069 Get It

DT‐01–06: Baseline FDG‐PET and volumetric MRI predicts Alzheimer's disease conversion from mild cognitive impairment: An ADNI study
Stonnington, Cynthia M. , Ayutyanont, Napatkamon , Reschke, Cole, Thyyagura, Pradeep, Protas, Hillary , Roontiva, Auttawut, Parks, Stephanie, Bauer, Robert, Lee, Wendy , Jagust, William, Foster, Norman L. , Weiner, Michael W. , Fleisher, Adam , Reiman, Eric M. , Chen, Kewei , Liu, Xiaofen , Koeppe, Robert A.

Alzheimer's & Dementia | October 9, 2013 | Volume: 9 | Issue: 4S_Part_21 | Pages: No page available

10.1016/j.jalz.2013.08.007 Get It

O2–03–01: Validation of the Alzheimer's Prevention Initiative Composite Cognitive Test Score
Ayutyanont, Napatkamon , Hendrix, Suzanne , Fleisher, Adam , Caselli, Richard J. , Monsell, Sarah E. , Tariot, Pierre N. , Reiman, Eric M. , Langbaum, Jessica B. S. , Chen, Kewei , Kukull, Walter A. , Bennett, David A.

Alzheimer's & Dementia | October 9, 2013 | Volume: 9 | Issue: 4S_Part_8 | Pages: No page available

10.1016/j.jalz.2013.04.147 Get It

O3‐03‐02: Composite cognitive endpoints with improved power to detect presymptomatic Alzheimer's disease treatment effects in APOE4 carriers: Findings from the Alzheimer's prevention initiative
Hendrix, Suzanne , Ayutyanont, Napatkamon , Tariot, Pierre N. , Fleisher, Adam , Caselli, Richard J. , Langlois, Carolyn, Reiman, Eric M. , Langbaum, Jessica B. S. , Chen, Kewei , Bennett, David A.

Alzheimer's & Dementia | August 1, 2011 | Volume: 7 | Issue: 4S_Part_14 | Pages: No page available

10.1016/j.jalz.2011.05.2401 Get It

O3‐06‐08: Sample size estimates for pre‐symptomatic Alzheimer's disease treatment/surrogate marker development trials in Apolipoprotein E4 homozygotes close to their estimated age at symptomatic onset
Reiman, Eric M. , Fleisher, Adam , Ayutyanont, Napatkamon , Reschke, Cole, Bandy, Dan, Reeder, Stephanie, Henslin, Bruce R. , Yee-Benedetto, Sandra C.H., Tariot, Piere N., Keppler, Jennifer, Alexander, Gene E. , Caselli, Richard J. , Chen, Kewei , Dueck, Amylou C. , Langbaum, Jessica B. S. , Liu, Xiaofen , Reeder, Stephanie, Pn, Tariot

Alzheimer's & Dementia | July 11, 2010 | Volume: 6 | Issue: 4S_Part_5 | Pages: No page available

10.1016/j.jalz.2010.05.434 Get It

Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease
Reiman, Eric M. , Chen, Kewei , Bandy, Daniel, Yu, Meixiang , Lee, Wendy , Ayutyanont, Napatkamon , Keppler, Jennifer, Reeder, Stephanie, Alexander, Gene E. , Klunk, William E. , Mathis, Chester A. , Price, Julie C. , Aizenstein, Howard , DeKosky, Steven T. , Caselli, Richard J. , Liu, Xiaofen , Reeder, Stephanie, Langbaum, Jessica B. S.

Proceedings of the National Academy of Sciences | April 3, 2009 | Volume: 106 | Issue: 16 | Pages: 6820-6825

10.1073/pnas.0900345106 Get It

Fibrillar amyloid-beta (Aβ) is found in the brains of many cognitively normal older people. Whether or not this reflects a predisposition to Alzheimer's disease (AD) is unknown. We used Pittsburgh Compound B (PiB) PET to characterize the relationship between fibrillar Aβ burden and this predisposition in cognitively normal older people at 3 mean levels of genetic risk for AD. Dynamic PiB PET scans, the Logan method, statistical parametric mapping, and automatically labeled regions of interest (ROIs) were used to characterize and compare cerebral-to-cerebellar PIB distribution volume ratios, reflecting fibrillar Aβ burden, in 28 cognitively normal persons (mean age, 64 years) with a reported family history of AD and 2 copies, 1 copy, and no copies of the apolipoprotein E (APOE) ε4 allele. The 8 ε4 homozygotes, 8 heterozygotes, and 12 noncarriers did not differ significantly in terms of age, sex, or cognitive scores. Fibrillar Aβ was significantly associated with APOE ε4 carrier status and ε4 gene dose in AD-affected mean cortical, frontal, temporal, posterior cingulate-precuneus, parietal, and basal ganglia ROIs, and was highest in an additional homozygote who had recently developed mild cognitive impairment. These findings suggest that fibrillar Aβ burden in cognitively normal older people is associated with APOE ε4 gene dose, the major genetic risk factor for AD. Additional studies are needed to track fibrillar Aβ accumulation in persons with different kinds and levels of AD risk; to determine the extent to which fibrillar Aβ, alone or in combination with other biomarkers and risk factors, predicts rates of cognitive decline and conversion to clinical AD; and to establish the role of fibrillar Aβ imaging in primary prevention trials.